| Patent Number |
Title Of Patent |
Date Issued |
| 6960564 |
Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
November 1, 2005 |
| Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the |
| 6958330 |
Polycyclic .alpha.-amino-.epsilon.-caprolactams and related compounds |
October 25, 2005 |
| Disclosed are polycyclic .alpha.-amino-.epsilon.-caprolactams and related compounds which are useful as synthetic intermediates in the preparation of inhibitors of .beta.-amyloid peptide release and/or its synthesis. |
| 6955818 |
Pour-on formulations |
October 18, 2005 |
| A non-irritant topically acceptable carrier selected from the group consisting of: a) i) at least one of tripropylene glycol methyl ether and dipropylene glycol methyl ether, and ii) at least one of alcohol, wool grease and propylene glycol, wherein (i) is present in an amount of at |
| 6953805 |
Excitatory amino acid receptor antagonists |
October 11, 2005 |
| The present invention provides novel compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I or Formula II in combination with a suitable carrier, diluent |
| 6951854 |
Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, |
October 4, 2005 |
| Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its syn |
| 6951840 |
Lipoglycopeptide antibiotics |
October 4, 2005 |
| Provided are novel lipoglycopeptides exhibiting bacterial signal peptidase inhibitory activity. Also provided are actinomycete strains that produce these lipoglycopeptides, methods of producing such lipoglycopeptides by culturing these strains, pharmaceutical compositions comprising thes |
| 6946579 |
Arylpiperazines having activity at the serotonin 1A receptor |
September 20, 2005 |
| A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1.sub.A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of |
| 6946467 |
Serine protease inhibitors |
September 20, 2005 |
| The compound 1-(indole-6-carbonyl-D-phenylglycinyl)-4-(1-methylpiperidin-4-yl)piperazin e and physiologically-tolerable salts thereof are factor Xa inhibitors useful for the treatment of thrombotic disorders. |
| 6939946 |
Ring modified cyclic peptide analogs |
September 6, 2005 |
| A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid |
| 6939890 |
sPLA2 inhibitors |
September 6, 2005 |
| A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. |
| 6936611 |
Serine protease inhibitors |
August 30, 2005 |
| Compounds of formula (I) ##STR1##in which R.sub.2, X, Y, Cy, L and Lp(D).sub.n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders. |
| 6936601 |
Compositions for treating pain |
August 30, 2005 |
| The present invention provides compositions for treating pain using an atypical antipsychotic compound that is seroquel in combination with another Drug Used in the Treatment of Pain. |
| 6933318 |
Topical organic ectoparasiticidal formulations |
August 23, 2005 |
| This invention provides topical ectoparasiticidal fomulations comprising an ectoparasiticide, preferably a pyrethroid or a spinosyn, a spreading agent at is a (C.sub.3 -C.sub.6) branched alkyl (C.sub.10 -C.sub.20) alkanoate, preferably isopropyl myristate, and optionally a miscibilizing |
| 6933313 |
Substituted carbazoles as inhibitors of sPLA2 |
August 23, 2005 |
| Carbazoles of formula (I) with R.sup.2 =hydroxyfunctional amide (hydroxamic or esters) are disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock. ##STR1## |
| 6930123 |
sPLA2 inhibitors |
August 16, 2005 |
| A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. |
| 6930120 |
Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists |
August 16, 2005 |
| Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH.sub.2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, ar |
| 6927210 |
Ectoparasiticidal aqueous suspension formulations of spinosyns |
August 9, 2005 |
| The invention provides a stable ectoparasiticidal aqueous suspension formulation of a spinosyn, comprising the spinosyn, or a physiologically acceptable derivative or salt thereof, milled to an average particle size of 1 to 15 microns, a surfactant in an amount effective to facilitate |
| 6924296 |
Antithrombotic agents |
August 2, 2005 |
| This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation a |
| 6924294 |
Excitatory amino acid receptor antagonists |
August 2, 2005 |
| The present invention provides novel compounds of Formula (I), or the pharmaceutically acceptable salts or prodrugs thereof, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine. |
| 6921827 |
Process for preparing 3-aryl-benzo{b} thiophenes |
July 26, 2005 |
| The present invention relates to a process for preparing a compound of formula (I): which includes cyclodehydrating a compound of formula (II): in the presence of an acid activated clay or acid activated zeolite catalyst and in the presence of a suitable solvent ##STR1## |
| 6919188 |
Pseudomycin production by Pseudomonas syringae |
July 19, 2005 |
| The present invention is directed to a family of unique antimycotic lipopeptide compounds produced by Pseudomonas viridiflava. The lipopeptides are effective against both human and plant fungal pathogens, and are typically characterized by their ability to inhibit growth of Candida a |
| 6916840 |
Spla2 inhibitors |
July 12, 2005 |
| A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. |
| 6916784 |
Cyclic peptide antifungal agents and process for preparation thereof |
July 12, 2005 |
| Provided are compounds of the formula (1): ##STR1##wherein R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --; R" and R'" are independently methyl or hydrogen; R adn R.sup.y are independently hydroxy or hydrogen; R.sub.1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R.sub.7 is hydroxy |
| 6911476 |
Sulfonamide derivatives |
June 28, 2005 |
| The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders. |
| 6911463 |
3-substituted oxindole .beta.-3 agonists |
June 28, 2005 |
| The present invention relates to a .beta.3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity. |
| 6906086 |
Methods for inhibiting bone loss |
June 14, 2005 |
| The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteo |
| 6906028 |
Stable insulin formulations |
June 14, 2005 |
| The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment |
| 6900353 |
Cyclopentyl sulfonamide derivatives |
May 31, 2005 |
| The present invention provides compounds of formula (I): useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders. |
| 6900196 |
Serine protease inhibitors |
May 31, 2005 |
| Compounds of formula (I) ##STR1##in which R.sub.2, X, Y, Cy, L and Lp(D).sub.n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders. |
| 6894064 |
Benzothiophenes, formulations containing same, and methods |
May 17, 2005 |
| This invention provides compounds of formula I ##STR1##and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range.The present invention further provides pharmaceutical compositions containing or form |
| 6881733 |
Serotonergic benzofurans |
April 19, 2005 |
| The present invention provides serotonergic benzofurans of Formula (I): where A, R, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as described in the specification. ##STR1## |
| 6878725 |
Serine protease inhibitors |
April 12, 2005 |
| Compounds of formula (I) ##STR1##in which R.sub.2, X, Y, Cy, L and Lp(D).sub.n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders. |
| 6872743 |
sPLA2 inhibitors |
March 29, 2005 |
| A novel class of tetracyclic compounds represented by the formula I ##STR1##wherein R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, and n are as defined is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Dise |
| 6869957 |
Non-peptide tachykinin receptor antagonists |
March 22, 2005 |
| This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pha |
| 6867198 |
Agents and methods for the treatment of proliferative diseases |
March 15, 2005 |
| The present invention provides selective kinase inhibitors of formula (I) ##STR1## |
| 6864262 |
1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceuticall |
March 8, 2005 |
| The present invention provides a compound of the formula (I) ##STR1## and the pharmaceutically acceptable salts and solvates thereof, which is useful for treating bladder over-activity or urinary incontinence. |
| 6855823 |
Selective iGluR5 receptor antagonists |
February 15, 2005 |
| The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR.sub.5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR.sub.5 |
| 6855725 |
Excitatory amino acid receptor antagonists |
February 15, 2005 |
| The present invention provides compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising compounds or Formula I or Formula II, and methods for treating neurological disorders and neurodegenerative diseases, |
| 6855715 |
Serine protease inhibitors |
February 15, 2005 |
| Compounds of formula (I) ##STR1##where R.sub.2, each X, L, Y, Cy, Lp, D and n are as defined in the specification, are serine protease inhibitors useful as antithrombotic agents. |
| 6846830 |
Naphtalene derivatives and their pharmaceutical use |
January 25, 2005 |
| Use of compounds of the formula (I) where A, E, R.sup.1, R.sup.2, p and q have the meanings given in the specification are GluR6 antagonists useful for the treatment of disorders of the central nervous system. |
| 6844344 |
Benzofuran derivatives |
January 18, 2005 |
| The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine ##STR1## |
| 6844338 |
Piperidyindoles as serotonin receptor ligands |
January 18, 2005 |
| A pharmaceutical compound of the formula (I) in which R.sup.1 and R.sup.2 are each hydrogen or C.sub.1-6 alkyl, R.sup.3 is --SR.sup.10, --SOR.sup.10, --SO.sub.2 R.sup.10, --COR.sup.10, --CH.sub.2 OH or --CONHR.sup.11, where R.sup.10 is C.sub.1-6 alkyl and R.sup.11 is hydrogen or C.su |
| 6841563 |
Aryloxy propanolamines for improving livestock production |
January 11, 2005 |
| Disclosed is a compound represented by structural formula (I): R1 is a substituted or unsubstituted aryl group. R2 and R3 are independently --H, a C1-C4 straight chained or branched alkyl group. R4 and R5 are independently --H, a C1-C4 straight chained or branched alkyl group or, tak |
| 6841371 |
Protein C derivatives |
January 11, 2005 |
| Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity and resistance to inactivation by serpins, compared to wild-type protein C and retain the biological activity of the wild-type human protein D. These derivatives will require e |
| 6835814 |
Protease resistant flint analogs |
December 28, 2004 |
| The invention relates to FLINT analogs that are to proteolysis in vivo and in vitro at amino acid position 218 of mature FLINT, clinical and therapeutic uses thereof, and pharmaceutical formulations comprising said analogs. |
| 6835733 |
Tropane linked benzofuran derivatives |
December 28, 2004 |
| The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine. ##STR1## |
| 6831095 |
Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors |
December 14, 2004 |
| A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. |
| 6828332 |
Piperidine derivatives as reuptake inhibitors |
December 7, 2004 |
| The present invention provides compounds of formula (I) and a method of inhibiting the reuptake of serotonin and antagonizing the serotonin receptor which comprises administering to a subject in need of such treatment an effective amount of a compound of formula (I). ##STR1## |
| 6828331 |
Growth hormone secretagogues |
December 7, 2004 |
| What is disclosed are growth hormone secretagogues, and their uses, of the formula ##STR1## wherein R1 is C.sub.6 H.sub.5 CH.sub.2 OCH.sub.2 --, C.sub.6 H.sub.5 (CH.sub.2)3-- or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C.sub.1 -C.sub.6 alkylpiperidin-1-yl or NR2R2; R2 are each in |
| 6825222 |
Modulators of peroxisome proliferator activated receptors |
November 30, 2004 |
| The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and ph |
